Cyclic-di-GMP (disodium)

Cyclic-di-GMP disodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research[1][2][3][4].

Product Specifications

CAS Number

[2222132-40-1]

Product Name Alternative

C-di-GMP (disodium) ; cyclic diguanylate (disodium) ; 5GP-5GP (disodium)

UNSPSC

12352005

Target

Endogenous Metabolite; STING

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cyclic-di-gmp-disodium.html

Purity

98.78

Solubility

H2O : 160 mg/mL (ultrasonic)

Smiles

O[C@@H]([C@H](N1C=NC2=C1N=C(N)NC2=O)O3)[C@H](OP(OC[C@@H]4[C@H]([C@H]([C@H](N5C=NC6=C5N=C(N)NC6=O)O4)O)O7)(O[Na])=O)[C@H]3COP7(O[Na])=O

Molecular Formula

C20H22N10Na2O14P2

Molecular Weight

734.37

References & Citations

[1]Karaolis DK, et al. 3',5'-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation. Biochem Biophys Res Commun. 2005 Apr 1;329 (1) :40-5. |[2]Steinberger O, et al. Elevated expression of the CD4 receptor and cell cycle arrest are induced in Jurkat cells by treatment with the novel cyclic dinucleotide 3',5'-cyclic diguanylic acid. FEBS Lett. 1999 Feb 5;444 (1) :125-9. |[3]Wang Z, et al. STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunol Immunother. 2015 Aug;64 (8) :1057-66. |[4]Jenal U, et al. Cyclic di-GMP: second messenger extraordinaire. Nat Rev Microbiol. 2017 May;15 (5) :271-284.

Shipping Conditions

Dry Ice

Storage Conditions

-80°C, protect from light, stored under nitrogen

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Citation 01

J Transl Med. 2025 Mar 4;23 (1) :271.|Nucleic Acids Res. 2025 Oct 28;53 (20) :gkaf1069.|Clin Transl Med. 2024 Aug;14 (8) :e1744.|NPJ Biofilms Microbiomes. 2024 Jun 20;10 (1) :51.|Gut Microbes. 2022 Jan-Dec;14 (1) :2119055.|Int J Biol Macromol. 2024 Sep 14:135660.|Mbio. 2021 Oct 26;12 (5) :e0119221.